March 11, 2024. The Court in the Acadia Pharmaceuticals securities matter (Southern District of California) certified a class of common stock investors. Plaintiffs allege that Acadia misled the market about the prospects of FDA approval for the company’s dementia-related psychosis treatment pimavanserin. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports and testimony on market efficiency.
Read more on this case at Law360.
Tagged securities litigation